RESUMEN
Myocardial infarction with no obstructive coronary artery disease (MINOCA) represents 6%-15% of all acute coronary syndromes, and women are disproportionately represented. MINOCA is an encompassing preliminary diagnosis, and emerging evidence supports a more expansive comprehensive diagnostic and therapeutic clinical approach. The current clinical practice update summarizes the latest evidence regarding the epidemiology, clinical presentation, and diagnostic evaluation of MINOCA. A cascaded approach to diagnostic workup is outlined for clinicians, for noninvasive and invasive diagnostic pathways, depending on clinical setting and local availability of diagnostic modalities. Evidence concerning the nonpharmacological and pharmacological treatment of MINOCA are presented and summarized according to underlying cause of MINOCA, with practical tips on the basis of expert opinion, outlining a real-life, evidence-based, comprehensive approach to management of this challenging condition.
Asunto(s)
Infarto del Miocardio , Salud de la Mujer , Humanos , Femenino , Canadá/epidemiología , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/terapia , Infarto del Miocardio/epidemiología , Sociedades Médicas , Enfermedad de la Arteria Coronaria/diagnóstico , Enfermedad de la Arteria Coronaria/terapiaRESUMEN
Cardiovascular disease (CVD) remains the leading cause of death globally. Although the burden of CVD risk factors tends to be lower in women, they remain at higher risk of developing complications when affected by these risk factors. There is still a lack of awareness surrounding CVD in women, both from a patient's and a clinician's perspective, especially among visible minorities. However, women who are informed about their heart health and who engage in decision-making with their healthcare providers are more likely to modify their lifestyle, and improve their CVD risk. A patient-centered care approach benefits patients' physical and mental health, and is now considered gold-standard for efficient patient care. Engaging women in their heart health will contribute in closing the gap of healthcare disparities between men and women, arising from sociocultural, socioeconomic, and political factors. This comprehensive review of the literature discusses the importance of engaging women in decision-making surrounding their heart health and offers tools for an effective and culturally sensitive patient-provider relationship.
Asunto(s)
Enfermedades Cardiovasculares , Toma de Decisiones , Humanos , Femenino , Enfermedades Cardiovasculares/psicología , Enfermedades Cardiovasculares/prevención & control , Salud de la Mujer , Participación del Paciente/psicología , Atención Dirigida al PacienteRESUMEN
Decades of research demonstrate the value of workplace diversity. Reports from individual countries show that women are underrepresented in internal medicine workforces. However, large pooled international studies are not available. This study investigates the current representation of women in the internal medicine workforce internationally and identifies specialties in which underrepresentation is evident. Peer-reviewed studies, government reports, and medical association reports were used to determine proportions of specialists and doctors training in internal medical specialties and in comparator surgical specialties. Data were available from Australia, Canada, England, New Zealand, the United States, Wales, Scotland, and Northern Ireland. A total of 380,263 doctors were studied, including 268,822 practicing specialist physicians (also known as attendings or consultants) and 53,226 doctors in internal medicine specialty training programs (also known as residents, fellows, advanced trainees, or specialist registrar trainees). Among practicing physician specialists, the rate of representation of women was 35% (95,195/268,822, p <0.001). Among trainees, the rate of representation of women was 43% (22,728/53,226, p <0.001). Among physician specialties evaluated, cardiology (15%, 4,152 of 27,328), gastroenterology (20%, 3,765 of 18,893), and respiratory/critical care (24%, 5,255 of 21,870) had the lowest representations of women compared with men (p <0.001 for all). Cardiology and particularly the subspecialty of interventional cardiology were clear outliers as the internal medicine specialties with the lowest representation of women at practicing specialist and trainee levels. In conclusion, this study is the largest international study of women in internal medicine specialties. It found that cardiology, gastroenterology, and respiratory/critical care specialties have the most substantial underrepresentation of women. These data are a global call to action to establish more successful strategies to provide a diverse and representative cardiology workforce.
Asunto(s)
Cardiología , Médicos , Masculino , Estados Unidos , Humanos , Femenino , Medicina Interna , Recursos Humanos , América del NorteRESUMEN
Up to 65% of women and approximately 30% of men have ischemia with no obstructive coronary artery disease (CAD; commonly known as INOCA) on invasive coronary angiography performed for stable angina. INOCA can be due to coronary microvascular dysfunction or coronary vasospasm. Despite the absence of obstructive CAD, those with INOCA have an increased risk of all-cause mortality and adverse outcomes, including recurrent angina and cardiovascular events. These patients often undergo repeat testing, including cardiac catheterization, resulting in lifetime healthcare costs that rival those for obstructive CAD. Patients with INOCA often remain undiagnosed and untreated. This review discusses the symptoms and prognosis of INOCA, offers a systematic approach to the diagnostic evaluation of these patients, and summarizes therapeutic management, including tailored therapy according to underlying pathophysiological mechanisms.
Jusqu'à 65 % des femmes et environ 30 % des hommes présentent une ischémie sans coronaropathie obstructive (INOCA [ischemia with no obstructive coronary artery disease]) révélée à la faveur d'une angiographie coronarienne invasive réalisée pour une angine stable. L'INOCA peut être attribuable à une dysfonction microvasculaire coronaire ou à un vasospasme coronaire. Malgré l'absence de coronaropathie obstructive, les patients atteints d'une INOCA présentent un risque accru de décès toutes causes confondues et d'événements indésirables, notamment l'angine récurrente et des événements cardiovasculaires. Ces patients sont souvent soumis à des examens répétés, dont le cathétérisme cardiaque, ce qui représente des dépenses de santé à vie qui rivalisent avec celles associées aux coronaropathies obstructives. Dans bien des cas, l'INOCA échappe au diagnostic et n'est pas traité. Dans le présent article de synthèse, nous nous penchons sur les symptômes et le pronostic de l'INOCA. Nous proposons une méthode systématique d'évaluation diagnostique de ces patients et résumons les modalités de sa prise en charge thérapeutique, notamment un traitement adapté aux mécanismes physiopathologiques sous-jacents.
RESUMEN
Women are under-represented among transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVr) operators. This review assesses the representation of women as patients and as proceduralists and trial authors in major structural interventions. Women are under-represented as proceduralists in structural interventions: only 2% of TAVR operators and 1% of TMVr operators are women. Only 1.5% of authors in landmark clinical TAVR and TMVr trials are interventional cardiologists who are women (4/260). Significant under-representation and under-enrolment of women in landmark TAVR trials is evident: the calculated participation-to-prevalence ratio (PPR) is 0.73, and in TMVr trials, the PPR is 0.69. Under-representation of women is also evident in registry data (PPR = 0.84 for TAVR registries and for TMVr registries). In structural interventional cardiology, women are under-represented as proceduralists, trial participants and patients. This under-representation has the potential to affect the recruitment of women to randomised trials, subsequent guideline recommendations, selection for treatment, patient outcomes and sex-specific data analysis.
RESUMEN
OBJECTIVES: Remote ischaemic conditioning (RIC) has been tested as a possible strategy for mitigating reperfusion injury in ST elevation myocardial infarction (STEMI) with primary percutaneous coronary intervention (PPCI). However, surrogate outcomes have shown inconsistent effects with lack of clinical correlation. METHODS: We performed a registry-based randomised study of patients with STEMI allocated to RIC (4 cycles of blood pressure cuff inflation to 200 mm Hg for 5 min of ischaemia followed by 5 min of reperfusion) or standard of care (SOC) during PPCI. We examined the associations of RIC on core laboratory measurements of myocardial perfusion, infarct size (IS), left ventricular (LV) performance and clinical outcomes. RESULTS: A total of 252 patients were enrolled. The median age was 61 (IQR: 55-70) years and 72.8% were male. Sum ST segment deviation resolution ≥50% was similar between RIC and SOC (65.2% vs 55.7%, p=0.269). In those with 3-day cardiovascular MRI (n=88), no difference in median (25th, 75th percentiles) IS (14.9% (4.5%, 23.1%) vs 16.1% (3.3%, 22.0%), p=0.980), LV dimensions (LV end-diastolic volume index: 78.7 (71.1, 91.2) mL/m2 vs 79.9 (71.2, 88.8) mL/m2, p=0.630; LV end-systolic volume index: 48.8 (35.7, 51.4) mL/m2 vs 37.9 (31.8, 47.5) mL/m2, p=0.551) or ejection fraction (50.0% (41.0%-55.0%) vs 50.0% (43.0%-56.0%), p=0.554) was demonstrated. Similar results were observed with 90-day cardiovascular MRI. At 1 year, the clinical composite of death, congestive heart failure, cardiogenic shock and recurrent myocardial infarction was similar in RIC and SOC (21.7% vs 13.3%, p=0.110). CONCLUSIONS: In a contemporary registry-based randomised study of patients with STEMI undergoing PPCI, adjunctive therapy with RIC did not improve myocardial perfusion, reduce IS or alter LV performance. Consequently, there was no difference in clinical outcomes within 1 year. TRIAL REGISTRATION NUMBER: NCT03930589.
Asunto(s)
Intervención Coronaria Percutánea , Infarto del Miocardio con Elevación del ST , Humanos , Isquemia/etiología , Masculino , Persona de Mediana Edad , Intervención Coronaria Percutánea/efectos adversos , Sistema de Registros , Infarto del Miocardio con Elevación del ST/diagnóstico por imagen , Infarto del Miocardio con Elevación del ST/terapia , Resultado del TratamientoRESUMEN
BACKGROUND: Women and the elderly with ST-elevation myocardial infarction (STEMI) experience longer treatment delays despite prehospital STEMI diagnosis and catheterization laboratory activation systems. It is not known what role specific STEMI referral systems might play in mediating this gap in care. We therefore examined sex- and age-based differences in STEMI treatment delay (TD) in different STEMI activation systems. METHODS: This observational comparative effectiveness study comprised 3 retrospective STEMI cohorts: a traditional hospital-based activation cohort (Cohort 1), an automated "physician-blind" prehospital activation cohort (Cohort 2), and a prehospital activation with real-time physician oversight cohort (Cohort 3). Outcomes of interest included sex and age group (< or ≥ 75 years) differences in suboptimal (> 90 minutes) first medical contact-to-device time (FMC-to-device) within each cohort, as well as independent predictors of suboptimal FMC-to-device and in-hospital mortality across cohorts. RESULTS: Five hundred-sixty STEMI activations were analyzed. In Cohort 1 (n = 179), women and those ≥ 75 were more likely to experience suboptimal FMC-to-device times (78.7% vs 36.4%, P = 0.02 and 85.0% vs 58.3%, < 0.01, respectively). Similar findings were observed in Cohort 3 (n = 109) (53.5% vs 32.9%, 56.5% vs 33.3%, respectively; P = 0.05, for both). In Cohort 2 (n = 272), however, there was no significant age-based difference (30.4% vs 21.7%, P = 0.18), and the gap was numerically lower but still significant for women (32.1% vs 20.1%, P = 0.04). When examining prehospital activation cohorts only, female sex (P = 0.03), off-hours presentation (P < 0.01), and physician oversight (P < 0.01) were independent predictors of longer FMC-to-device times. Age ≥ 75 (P < 0.01), Killip class (P < 0.01), and female sex (P = 0.04) were independently associated with in-hospital mortality. CONCLUSIONS: Automated "physician-blind" STEMI activation was associated with a reduced TD gap in women and the elderly, suggesting possible systemic bias. Appropriately powered confirmatory studies are required, but incorporating automated diagnosis and catheterization laboratory activation may be a solution to treatment gaps in STEMI care.
INTRODUCTION: Les femmes et les personnes présentant ont un infarctus du myocarde avec élévation du segment ST (STEMI) subissent de plus longs retards de traitement en dépit du diagnostic préhospitalier de STEMI et des systèmes d'activation de laboratoires de cathétérisme. On ignore le rôle que pourraient jouer les systèmes d'aiguillage des personnes atteintes de STEMI pour combler cette lacune en matière de soins. Nous avons donc examiné les différences selon le sexe et l'âge dans le retard de traitement du STEMI des différents systèmes d'activation de laboratoire en présence de STEMI. MÉTHODES: La présente étude comparative sur l'efficacité regroupait trois cohortes rétrospectives de STEMI : une cohorte traditionnelle d'activation à l'hôpital (cohorte 1), une cohorte d'activation du laboratoire lors de diagnostic préhospitalier automatisé « à l'insu du médecin ¼ (cohorte 2) et une cohorte d'activation du laboratoire de diagnostic préhospitalier dont la surveillance est assurée par un médecin en temps réel (cohorte 3). Les critères d'intérêt étaient les différences selon le sexe et le groupe d'âge (< ou ≥ 75 ans) dans le taux d'intervalle sous-optimal entre la première prise de contact avec les services médicaux et la pose d'un dispositif (> 90 minutes) au sein de chaque cohorte, ainsi que les prédicteurs indépendants de l'intervalle sous-optimal entre la première prise de contact avec les services médicaux et la pose d'un dispositif et la mortalité à l'hôpital de toutes les cohortes. RÉSULTATS: Cinq cents soixante (560) activations de diagnostic de STEMI ont fait l'objet d'une analyse. Dans la cohorte 1 (n = 179), les femmes et les personnes ≥ 75 ans étaient plus susceptibles de subir des intervalles sous-optimaux entre la première prise de contact avec les services médicaux et la pose d'un dispositif (78,7 % vs 36,4 %, P = 0,02 et 85,0 % vs 58,3 %, < 0,01, respectivement). Nous avons observé des résultats similaires dans la cohorte 3 (n = 109) (53,5 % vs 32,9 %, 56,5 % vs 33,3 %, respectivement ; P = 0,05, pour les deux). Toutefois, dans la cohorte 2 (n = 272), il n'y avait aucune différence significative selon l'âge (30,4 % vs 21,7 %, P = 0,18) et l'écart était numériquement plus faible, mais encore significatif chez les femmes (32,1 % vs 20,1 %, P = 0,04). Lorsque nous examinions seulement les cohortes d'activation du laboratoire lors de diagnostic préhospitalier, le sexe féminin (P = 0,03), la survenue dans les heures creuses (P < 0,01) et la surveillance du médecin (P < 0,01) étaient des prédicteurs indépendants d'intervalles plus longs entre la première prise de contact avec les services médicaux et la pose d'un dispositif. L'âge ≥ 75 ans (P < 0,01), la classification de Killip (P < 0,01) et le sexe féminin (P < 0,04) étaient indépendamment associés à la mortalité à l'hôpital. CONCLUSIONS: L'activation du laboratoire lors de diagnostic automatisé du STEMI « à l'insu du médecin ¼ a été associée à une réduction de l'écart dans le retard de traitement chez les femmes et les personnes âgées. Ceci indique un possible biais systémique. Des études confirmatives d'une puissance suffisante sont nécessaires, mais l'incorporation du diagnostic et de l'activation du laboratoire de cathétérisme atuomatisés peut être une solution aux écarts de traitement dans les soins de STEMI.
RESUMEN
BACKGROUND: ST-elevation myocardial infarction diagnosis at first medical contact (FMC) and prehospital cardiac catheterization laboratory (CCL) activation are associated with reduced total ischemic time and therefore have become the dominant ST-elevation myocardial infarction referral method in primary percutaneous coronary intervention systems. We sought to determine whether physician oversight was associated with improved diagnostic performance in a prehospital CCL activation system and what effect the additional interpretation has on treatment delay. METHODS: Between 2012 and 2015, all patients in 2 greater Montreal catchment areas with a chief symptom of chest paint or dyspnea had an in-the-field electrocardiogram (ECG). A machine diagnosis of "acute myocardial infarction" resulted either in automatic CCL (automated cohort without oversight) or transmission of the ECG to the receiving centre emergency physician for reinterpretation before CCL activation. System performance was assessed in terms of the proportion of false positive and inappropriate activations (IA), as well as the proportion of patients with FMC-to-device times ≤ 90 minutes. RESULTS: Four hundred twenty-eight (428) activations were analyzed (311 automated; 117 with physician oversight). Physician oversight tended to decrease IAs (7% vs 3%; P = 0.062), but was also associated with a smaller proportion of patients achieving target FMC-to-device (76% vs 60%; P < 0.001). There was no significant effect on the proportion of false positive activation. CONCLUSIONS: Real-time physician oversight might be associated with fewer IAs, but also appears to have a deleterious effect on FMC-to-device performance. Identifying predictors of IA could improve overall performance by selecting ECGs that merit physician oversight and streamlining others. Larger clinical studies are warranted.
CONTEXTE: Un diagnostic d'infarctus du myocarde avec élévation du segment ST au moment du premier contact avec un professionnel de la santé et l'activation du processus de cathétérisme cardiaque avant l'arrivée à l'hôpital sont associés à une réduction de la durée totale de l'épisode ischémique, et sont donc désormais la méthode de préférence en cas d'infarctus du myocarde avec élévation du segment ST dans les établissements où l'intervention coronarienne percutanée primaire est possible. Nous avons voulu déterminer si la supervision par un médecin était associée à une amélioration de la justesse du diagnostic dans un tel contexte et les répercussions d'une interprétation additionnelle sur les délais de traitement. MÉTHODOLOGIE: De 2012 à 2015, tous les patients de deux zones desservies du Grand Montréal qui présentaient comme principal symptôme une douleur à la poitrine ou une dyspnée ont subi un électrocardiogramme (ECG) sur le terrain. Un diagnostic d'infarctus aigu du myocarde posé par l'appareil a automatiquement donné lieu à l'activation du processus de cathétérisme cardiaque (cohorte automatisée sans supervision) ou à la transmission de l'ECG à l'urgentologue de l'établissement où le patient était conduit pour la réinterprétation des résultats avant l'activation du processus de cathétérisme cardiaque. La performance du système a été évaluée en fonction de la proportion de faux positifs et d'activations inappropriées, ainsi que de la proportion de patients chez qui le délai entre le premier contact avec un professionnel de la santé et l'intervention était ≤ 90 minutes. RÉSULTATS: Quatre cent vingt-huit (428) activations du processus ont été analysées (311 automatisées; 117 après la supervision par un médecin). La supervision par un médecin était associée à une baisse non significative des activations inappropriées du processus (7 % vs 3 %; p = 0,062), mais était aussi associée à une plus faible proportion de patients chez qui le délai visé entre le premier contact avec un professionnel de la santé et l'intervention était respecté (76 % vs 60 %; p < 0,001). Aucun effet significatif quant à la proportion de faux positifs n'a été observé. CONCLUSIONS: La supervision en temps réel par un médecin pourrait être associée à une réduction des activations inappropriées du processus de cathétérisme cardiaque urgent, mais pourrait également nuire aux résultats quant au délai entre le premier contact avec un professionnel de la santé et l'intervention. L'identification des facteurs prédictifs d'une activation inappropriée du processus pourrait améliorer les résultats globaux en permettant de choisir les résultats d'ECG qui mériteraient d'être passés en revue par le médecin, et en déclenchant le processus habituel pour les autres. Des études cliniques de plus grande envergure sont de mise.
RESUMEN
BACKGROUND: The level of representation of women in cardiology remains low compared to that of men, particularly in leadership positions. We evaluated gender disparity in the authorship of Canadian Cardiovascular Society (CCS) guidelines. METHODS: All CCS guidelines from 2001-2020 were identified. Gender was assessed based on pronoun use in the biographies and social media of the authors. Only primary panel authors were included in our analysis. Stratified analyses were performed based on subspecialties. RESULTS: A total of 76 guidelines were identified, with 1172 authors (26% women, 74% men, P < 0.0001), with no significant change in percentage of women authors over 2 decades, (37.1% in 2001, 36.3% in 2020, P = 0.34). Inclusion of women as authors occurred less frequently than inclusion of men in general cardiology guidelines (20.1% vs 79.9%, P < 0.0001) and all subspecialties-heart failure (36.4% vs 63.6%, P < 0.0001), interventional cardiology (12.6% vs 87.4%, P < 0.0001), electrophysiology (20.2% vs 79.8%, P < 0.0001), and pediatric cardiology (41.7% vs 58.3%, P = 0.02). It was less likely for women to be a chair or cochair of a guideline writing committee, compared with men (20.1% vs 79.8%, P < 0.0001). There were 609 unique authors (25.6% women, 74.4% men, P < 0.0001), 542 unique medical doctorate (MD) authors (20.7% women, 79.3% men, P < 0.0001), and 67 unique non-MD authors (65.7% women, 34.3% men, P = 0.0003). CONCLUSIONS: There is a persistent shortfall in the inclusion of women authors for CCS guidelines, which has not changed over time. Further efforts are required to promote women's inclusion in leadership roles, which may lead to authorship of the guidelines.
INTRODUCTION: La représentation des femmes en cardiologie demeure faible par rapport à celle des hommes, particulièrement dans les positions de leadership. Nous avons évalué la disparité entre les sexes de la paternité des lignes directrices de la Société canadienne de cardiologie (SCC). MÉTHODES: Nous avons relevé toutes les lignes directrices de la SCC de 2001 à 2020. Nous avons déterminé le sexe en fonction de l'utilisation du pronom dans les biographies et les médias sociaux des auteurs. Seuls les auteurs du panel principal ont été ajoutés à notre analyse. Nous avons réalisé les analyses stratifiées en fonction des sous-spécialités. RÉSULTATS: Nous avons relevé un total de 76 lignes directrices, qui regroupaient 1 172 auteurs (26 % de femmes, 74 % d'hommes, P < 0,0001). Par conséquent, il n'y avait eu aucun changement significatif dans le pourcentage des autrices au cours de deux décennies (37,1 % en 2001, 36,3 % en 2020, P = 0,34). L'intégration d'autrices est en général apparue moins fréquemment que l'intégration d'auteurs dans les lignes directrices de cardiologie (20,1 % vs 79,9 %, P < 0,0001) et de toutes les sous-spécialités (insuffisance cardiaque [36,4 % vs 63,6 %, P < 0,0001], cardiologie interventionnelle [12,6 % vs 87,4 %, P < 0,0001], électrophysiologie [20,2 % vs 79,8 %, P < 0,0001] et cardiologie pédiatrique [41,7 % vs 58,3 %, P = 0,02]). Il était moins probable que les femmes président ou co-président le comité de rédaction des lignes directrices que les hommes (20,1 % vs 79,8 %, P < 0,0001). Il y avait 609 auteurs individuels (25,6 % de femmes, 74,4 % d'hommes, P < 0,0001), 542 auteurs médecins (M.D.) individuels (20,7 % de femmes, 79,3 % d'hommes, P < 0,0001) et 67 auteurs non médecins individuels (65,7 % de femmes, 34,3 % d'hommes, P = 0,0003). CONCLUSIONS: Des lacunes dans l'intégration des autrices aux lignes directrices de la SCC persistent et demeurent inchangées depuis des années. D'autres efforts sont nécessaires pour encourager l'intégration des femmes dans des rôles de leadership, qui pourront mener à la paternité des lignes directrices.
RESUMEN
Partial anomaly of the pulmonary venous return is a rare congenital condition treated with surgical redirection of the blood flow through the creation of a conduit to the left atrium. We report the case of a stenotic pulmonary vein to left atrium conduit successfully treated with the implantation of a drug-eluting stent. Pulmonary vein or conduit stenosis is generally treated with balloon dilation or bare-metal stent but is often met with underwhelming outcomes. Given the successful outcome of the case presented, drug-eluting stents may represent an attractive treatment option in suitable anatomies.
Les anomalies partielles du retour veineux pulmonaire sont des anomalies congénitales rares traitées par une intervention chirurgicale visant à rediriger le flux sanguin par la création d'un conduit vers l'oreillette gauche. Nous rapportons un cas de veine pulmonaire sténosée au conduit de l'oreillette gauche pour laquelle l'implantation d'une endoprothèse médicamentée s'est avérée une réussite. La sténose de la veine pulmonaire ou du conduit est généralement traitée par la dilation par ballonnet ou l'implantation d'une endoprothèse non médicamentée nu, mais les résultats sont souvent décevants. Compte tenu des résultats favorables observés pour ce cas, les endoprothèses à élution de médicamentées peuvent constituer une option attrayante de traitement dans les cas où l'anatomie s'y prête.
Asunto(s)
Infarto de la Pared Anterior del Miocardio/tratamiento farmacológico , Actitud , Cardiología , Fibrinolíticos/uso terapéutico , Infarto del Miocardio con Elevación del ST/tratamiento farmacológico , Sociedades Médicas , Disfunción Ventricular Izquierda/etiología , Infarto de la Pared Anterior del Miocardio/complicaciones , Canadá , Cardiólogos , Humanos , Infarto del Miocardio con Elevación del ST/complicaciones , Disfunción Ventricular Izquierda/diagnóstico , Disfunción Ventricular Izquierda/tratamiento farmacológicoRESUMEN
Antithrombotic management of STEMI patients with apical dysfunction, but without demonstrable thrombus, is controversial. Triple antithrombotic therapy (TATT, defined as the addition of oral anticoagulation to dual antiplatelet therapy, or DAPT) may be associated with increased bleeding, while DAPT alone may not adequately protect against cardio-embolic events. We undertook a dual-center study of anterior STEMI patients treated with primary PCI (pPCI) from 2013 to 2015 and presenting presumed new apical dysfunction. The Centre hospitalier de l'Université de Montréal (CHUM) uses a strategy of selective TATT, whereas the Centre hospitalier universitaire de Sherbrooke (CHUS) has favored ticagrelor-based DAPT for all patients since 2013. The primary composite outcome consisted of death, MI, stroke, revascularization, and BARC 3 to 5 bleeding up to 4-months follow-up. We identified 177 cases (69 CHUM; 108 CHUS). Baseline characteristics were similar and procedural success was high (97%). There was no difference in post-procedure LVEF (39 ± 9% vs 37 ± 9%) or the extent of apical dysfunction. The primary composite outcome occurred in 27% with the selective TATT strategy compared to 19% with ticagrelor-DAPT (p = 0.342). Thus, this retrospective dual-center analysis does not support a strategy of conventional TATT over ticagrelor-based DAPT for patients with apical dysfunction following anterior STEMI treated with pPCI. A pragmatic randomized trial is needed to provide a definitive answer to this clinical conundrum.
Asunto(s)
Anticoagulantes/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Infarto del Miocardio con Elevación del ST/tratamiento farmacológico , Ticagrelor/uso terapéutico , Disfunción Ventricular Izquierda/etiología , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Infarto del Miocardio con Elevación del ST/complicaciones , Infarto del Miocardio con Elevación del ST/patología , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Anterior myocardial infarction (MI) with apical dysfunction is associated with an increased risk of left ventricular thrombus (LVT) formation and systemic embolism (SE). However, the role for prophylactic anticoagulation in current practice is a matter of debate. METHODS: We conducted a systematic review of peer-reviewed original articles in either English or French on the benefit of combining anticoagulation with standard therapy for the prevention of LVT/SE after MI by searching PubMed, Ovid/MedLine/Embase, the Cochrane Library, and Google Scholar. RESULTS: Of 7382 identified records, 14 were retained for analysis. Nine articles addressed anticoagulation for patients not treated with percutaneous coronary intervention (PCI). Another 5 included at least some patients treated with PCI. Only 1 study specifically addressed exclusively a primary PCI population. Some studies showed a benefit for combining anticoagulation with standard therapy in patients not treated with PCI, but results were inconsistent. No evidence of benefit was reported when PCI patients were included and 1 study reported a signal for net harm. There was important interstudy heterogeneity and methodological limitations. Studies were likely individually underpowered. CONCLUSIONS: The available studies of LVT/SE prevention after MI lacked statistical power and are heterogeneous in terms of treatments, revascularization methods, background medical therapy, and study design. We conclude that there is presently no compelling evidence for or against combining anticoagulation with standard therapy for post-MI patients with apical dysfunction after primary PCI, and inconsistent evidence supporting prophylaxis after thrombolysis. An appropriately powered randomized trial is required to answer this clinically relevant question.